Outcomes of retroperitoneal lymph node dissection for testicular cancer by a high volume surgeon from Australia: a case for centralisation.

Background: There are few studies examining retroperitoneal lymph node dissection (RPLND) for testicular cancer in Australia. This study examines the perioperative outcomes, complications and survival rates following RPLND, by a high volume, single surgeon. Methods: A retrospective, case series of a single surgeon, multi‐centre study included all patients who underwent RPLND following testicular cancer at Westmead Public Hospital, Westmead Private Hospital, and Macquarie University Hospital 2005–2020. One hundred one patients identified, with 94 having sufficient available data. Results: At time of operation, median age was 29.5 years. 84.2% had T1 or T2 primary tumours at diagnosis. Most common RPLND indication was residual mass post‐chemotherapy (92.6%), with bleomycin, etoposide and cisplatin (BEP)x3 and BEPx4 most common chemotherapy regimens (50% and 35% respectively). Post‐chemotherapy, largest residual mass ranged from 0.9 to 20 cm (median 3.32 cm). Post‐chemotherapy, 95.7% masses were found in retroperitoneum (64.4% para‐aortic region). 93.6% had open approach. 42.5% had bilateral nerve sparing. Majority (97.1%) did not require blood transfusion. No complications reported in 52.1% of patients. No deaths recorded within 90 days of surgery. At time of analysis, 91.5% had recurrence free survival, and 92.6% overall survival, at a median follow‐up since surgery of 47.5 months (range 11 to 200 months). Conclusions: This retrospective study, addressing peri‐operative surgical outcomes for RPLND surgery in Australia, is comparable to high‐volume international urological centre studies, and shows that centralisation of post‐chemotherapy RPLND to an experienced surgeon, results in low perioperative morbidity and mortality. [ABSTRACT FROM AUTHOR]